MedicalCV AtriLaze 1064nm laser:
This article was originally published in Clinica
Executive Summary
The US FDA has given MedicalCV 510(k) market clearance to expand the functionality of its AtriLaze surgical ablation system for treating atrial fibrillation (AF), by allowing the device to deliver 1064nm wavelength laser energy. The system is already cleared for the delivery of 810nm laser light. The new wavelength optimises the application of laser energy to cardiac tissue and is particularly suitable for the miniaturisation required to use laser technology through smaller access ports said MedicalCV. This brings the firm a significant step closer to delivering a "truly stand-alone, minimally invasive" AF therapy procedure, the Inver Grove Heights, Minnesota company added.